Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 4/20 | 0.75 |
| ▸ | TERT | O14746 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.54 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | TK1 | P04183 | 1/20 | 0.52 |
| ▸ | TYMS | P04818 | 1/20 | 0.52 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29607650 | 1.00 | DTYMK (0.75) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL29769834 | 1.00 | DTYMK (0.75) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL30122220 | 1.00 | DTYMK (0.75) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL17268344 | 0.95 | DTYMK (0.74) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL8613042 | 0.95 | DTYMK (0.74) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL8612856 | 0.95 | DTYMK (0.74) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL16983788 | 0.93 | DTYMK (0.66) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL30632043 | 0.93 | DTYMK (0.66) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL16979766 | 0.93 | DTYMK (0.66) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL9160842 | 0.93 | DTYMK (0.83) | DTYMKTERTPOLBENPP1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 479 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629415-B2 | Vaccine adjuvants | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2026-05-19 | — | — | US | claimed |
| US-20260108454-A1 | Innate Targeting of Adoptive Cellular Therapies | QU BIOLOGICS INC (CA) | 2026-04-23 | — | — | US | claimed |
| US-12594291-B2 | Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen | ALPHA TAU MEDICAL LTD (IL) | 2026-04-07 | — | — | US | claimed |
| EP-4692372-A1 | UNIVERSAL LANDING PLATFORM | UNIVERCELLS FRANCE SAS (FR) | 2026-02-11 | — | — | EP | claimed |
| EP-3873598-B1 | INTRATUMORAL ALPHA-EMITTER RADIATION AND ACTIVATION OF CYTOPLASMATIC SENSORS FOR INTRACELLULAR PATHOGEN | ALPHA TAU MEDICAL LTD (IL) | 2025-07-02 | — | — | EP | claimed |
| US-20250186486-A1 | POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION | BAYLOR COLLEGE OF MEDICINE (US) | 2025-06-12 | — | — | US | claimed |
| CN-120118149-A | Polypeptide for inhibiting TBK1 and inflammation and application thereof | 中国科学院武汉病毒研究所 | 2025-06-10 | — | — | CN | claimed |
| EP-4559479-A2 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-05-28 | — | — | EP | claimed |
| EP-4493166-A1 | POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION | Baylor College of Medicine (US) | 2025-01-22 | — | — | EP | claimed |
| CN-119278032-A | Enhancement of persistent antitumor immunity by multifactorial immunomodulation | 贝勒医学院 | 2025-01-07 | — | — | CN | claimed |
| US-20230093460-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | YALE UNIVERSITY (US) | 2023-03-23 | — | — | US | claimed |
| US-20230079745-A1 | COMPOSITIONS COMPRISING BACTERIALLY DERIVED MINICELLS AND METHODS OF USING THE SAME | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2023-03-16 | — | — | US | claimed |
| WO-2023034864-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | YALE UNIVERSITY (US) | 2023-03-09 | — | — | WO | claimed |
| CN-115611988-A | Compounds for targeted immunotherapy | 博笛生物科技有限公司 | 2023-01-17 | — | — | CN | claimed |
| WO-2023278897-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | YALE UNIVERSITY (US) | 2023-01-05 | — | — | WO | claimed |
| EP-4097473-A1 | METHODS FOR ASSIGNING A PHENOTYPIC SIGNATURE FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DE) | 2022-12-07 | — | — | EP | claimed |
| WO-2022215079-A1 | NANOVACCINES FOR TREATMENT OF VIRAL DISEASES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-10-13 | — | — | WO | claimed |
| WO-2022047424-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | YALE UNIVERSITY (US) | 2022-03-03 | — | — | WO | claimed |
| CN-114081961-A | Composite nano-particles, preparation method and application | 中国科学技术大学 | 2022-02-25 | — | — | CN | claimed |
| WO-2022032043-A1 | DENDRITIC CELL ACTIVATING THERAPY AS AN ADJUNCT TO RADIATION THERAPY | MONTEFIORE MEDICAL CENTER (US) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108454-A1 | Innate Targeting of Adoptive Cellular Therapies | MYD88, TLR3, TLR9 | DTYMK 777/4885TERT 3595/4885POLB 2781/4885 |
| US-12629415-B2 | Vaccine adjuvants | STING1, TLR9, TLR3 | DTYMK 207/4885TERT 1293/4885POLB 563/4885 |
| US-12594291-B2 | Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen | STING1, IFNAR1, IFNG | DTYMK 1783/4885TERT 4566/4885POLB 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.